High Flow Nasal Cannula Market

Analysis by Type (Active Humidifier, Single Heated Tube, Air Blender, and Nasal Cannula); by Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, Acute Heart failure, and Others); and by End User (Hospitals & Clinics, Ambulatory Care Centers, Long-Term Care Centers, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now
Report ID: 4575 | Published On: Feb 24, 2023
Request Free Sample Copy

Global High Flow Nasal Cannula Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global high flow nasal cannula market is estimated to garner a revenue of USD 17 Billion by the end of 2033 by growing at a CAGR of ~12% over the forecast period, i.e., 2023 – 2033. Further, the market produced a revenue of USD 9 Billion in the year 2022. The growth of the market is primarily attributed to the radically increasing cases of asthma along with chronic obstructive pulmonary diseases across the globe. As per the World Health Organization, globally, asthma is expected to have killed 455 000 people in 2019 and impacted 262 million people in the same year. Increasing air pollution is caused by the presence of particulate matter and ozone, and an increasing number of indoor air pollutants, which include tobacco smoke, dust mites, cockroaches, mold & pesticides. The pollution caused by fossil fuel combustion, the growing number of industries, transportation, and the rising use of chemicals across the world is estimated to propel the growth of the market.

High-Flow-Nasal-Cannula-Market-overview.Get more information on this report:Download Sample PDF

The nasal cannula is used in cases where people are not able to breathe or get sufficient oxygen for the proper functioning of the body. This is a common phenomenon among patients who are suffering from asthma, COPD, or any other respiratory illness. In addition to this, the market is estimated to grow on the basis of the rising prevalence of asthma and respiratory tract illnesses among children across the world. Also, asthma is the most common chronic condition affecting children as per the reports. As per the estimations, about 5.1 million asthmatic children are under the age of 18. Moreover, about, 11 Americans die from asthma every day, and asthma-related deaths reached to 4,145 in the year 2020. Besides this, the launch of novel advanced products by the key manufacturers is another major factor that is fueling the growth of the market over the projected period.

Get more information on this report: Request Sample PDF

Global High Flow Nasal Cannula Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 9 Billion

Forecast Year Market Size (2033)

~ USD 17 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global High Flow Nasal Cannula Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Geriatric Population across the Globe with Reduced Immunity – In people 65 years of age or older, asthma is common. Asthma affects about 7.8% of older individuals in the US. Asthma and other respiratory illnesses are frequent and more common in elderly people. With aging, the immunity to fight back illness slows down and, with that, the geriatric population becomes more prone to chronic illness. Hence, the rising geriatric population and the increasing prevalence of asthma among the elderly are estimated to drive market growth.

  • Growing Investment in Research and Development Owing to Increasing Funds – According to data compiled by the World Bank, the global research and development expenditures made up 2.23% of GDP in 2018.

  • Increasing Spending on Healthcare with Rising Awareness of Health Among People – For instance, in the last 20 years, global health spending has increased overall and reached USD 8.5 trillion in 2019 with 9.8% of GDP, up from 8.5 percent in 2000.

  • Rising Prevalence of Asthma with Rising Respiratory Diseases – The increasing demand for the chronic respiratory diseases treatment is expected to boost the market’s growth in the upcoming years. Over 20 million Americans above the age of 18 suffer from asthma, and adult females are more likely than adult males to be affected. Compared to 6.1 percent of adult males, it affects roughly 9.8 percent of adult females.
  • Growing Adoption of Ambulatory Surgeries Around the World – It was observed that over the past 25 years, the number of ambulatory surgeries performed at community hospitals in the United States has steadily increased, rising from 13.4 million in 1995 to 19.2 million in 2018.


  • Side Effects of Using High Flow Nasal Cannula – While using high flow nasal cannulas, unwarmed and dry gas is estimated to be harmful to people with respiratory failure. Breathing dry air produces excessive water loss by the nasal mucosa, which may limit the nasal mucociliary clearance rate through alterations in the rheological characteristics or adhesiveness of nasal mucus and/or ciliary pulse shortening. This factor is anticipated to hinder the growth of the market during the forecast period.
  • Suitability Issues for Long-Term Usage
  • High Cost of the Product in the Market

Market Segmentation

The global high flow nasal cannula market is segmented and analyzed for demand and supply by application into acute respiratory failure, chronic obstructive pulmonary disease (COPD), acute heart failure, and others. Among these segments, the COPD segment is estimated to garner the largest market share as per the market analysis. COPD is a common pulmonary disease that affects the lungs of the patient. Furthermore, the increasing number of COPD cases is owing to the growing occupational inhalation of chemicals or dust. In addition, long-term exposure to tobacco smoke, indoor air pollution from allergens including animal fur, plant pollen, cooking smoke from cow dung or wood, the presence of respiratory infections, and any genetic deficiency are estimated to cause COPD. Across the world, over 3.23 million people died from COPD in 2019, as per the World Health Organization. The treatment with the high flow oxygen via nasal cannula helps to reduce respiratory rate and supports COPD patients with acute hypercapnic respiratory illness. It improves gas exchange in the blood to purify deoxygenated blood. This increase in demand for high flow nasal cannula application in COPD patients is anticipated to surge the segment’s growth in the market.

The global high flow nasal cannula market is also segmented and analyzed for demand and supply by end-user into hospitals and clinics, ambulatory care centers, long-term care centers, and others. Out of these, the hospitals & clinics segment is estimated to gain the largest market share by the end of 2033 on the back of the requirement for high flow nasal cannulas in hospitals and clinics, which is based on usage for a predetermined number of patients. Moreover, the number of hospitals and surgeries is growing, thus increasing the usage of the nasal cannula in the hospital is further predicted to boost the segment’s growth in the market. Further, approximately 40 to 50 million major surgeries are performed in the USA every year, and about 20 million in Europe, out of 310 million surgeries across the world.  

Our in-depth analysis of the global high flow nasal cannula market includes the following segments:

                By Type

  • Active Humidifier
  • Single Heated Tube
  • Air Blender
  • Nasal Cannula

                By Application

  • Acute Respiratory Failure
  • Chronic Obstructive Pulmonary Disease
  • Acute Heart failure
  • Others

                 By End-User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Long-Term Care Centers
  • Others

Global High Flow Nasal Cannula Market Regional Synopsis

The Asia Pacific high flow nasal cannula market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the growing geriatric and pediatric population, along with the increasing prevalence of asthma in the region. By 2050, one in four individuals in the region of Asia Pacific is estimated to get older than 60, and the incidence of asthma in the elderly population is about 1.3 to 15.3% compared to 5 percent of adults in the region, as per the reports. Moreover, with the rising cases of chronic respiratory diseases, there is also a surge in the number of surgeries conducted in the region every year. Along with this, the growing healthcare infrastructure, and improving healthcare facilities in the region are estimated to drive market growth in the region during the forecast period. The increasing urbanization from growing industries releases harmful gases and chemicals into the environment. In addition, the increasing automobile industry is also estimated to rise air pollution owing to elevating vehicles on the road.

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Global High Flow Nasal Cannula Market

    • Armstrong Medical Ltd

      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eakin Healthcare Group
    • ResMed Corp.
    • Teleflex Incorporated
    • Vapotherm, Inc.
    • Becton, Dickinson, and Company
    • Smiths Group plc
    • CU Medical Systems, Inc
    • Flexicare Medical Limited

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the high flow nasal cannula market?

Ans: Rising geriatric population, growing investment in research and development are the major factors driving the market growth.

2) What would be the CAGR of high flow nasal cannula market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the high flow nasal cannula market growth?

Ans: The side effects and high cost of the product are estimated to be the restraining factor for the market growth.

4) Which region will provide more business opportunities for growth of high flow nasal cannula market in future?

Ans: The market in Asia Pacific region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the high flow nasal cannula market?

Ans: The major players in the market are Armstrong Medical Ltd, Eakin Healthcare Group, ResMed Corp., Teleflex Incorporated, Vapotherm, Inc., Becton, Dickinson and Company, Smiths Group plc, CU Medical Systems, Inc, Flexicare Medical Limited, TEIJIN LIMITED.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the high flow nasal cannula market?

Ans: The market is segmented by type, application, end user, and by region.

8) Which segment captures the largest market size in end user segment in the high flow nasal cannula market?

Ans: The hospitals and clinic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample